[go: up one dir, main page]

WO2023036041A1 - Anticorps agoniste anti-4-1bb et son utilisation - Google Patents

Anticorps agoniste anti-4-1bb et son utilisation Download PDF

Info

Publication number
WO2023036041A1
WO2023036041A1 PCT/CN2022/116428 CN2022116428W WO2023036041A1 WO 2023036041 A1 WO2023036041 A1 WO 2023036041A1 CN 2022116428 W CN2022116428 W CN 2022116428W WO 2023036041 A1 WO2023036041 A1 WO 2023036041A1
Authority
WO
WIPO (PCT)
Prior art keywords
amino acid
acid sequence
acid residues
seq
substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/CN2022/116428
Other languages
English (en)
Chinese (zh)
Inventor
孟祥雪
史继亚
介淼星
任志衡
李文佳
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sunshine Lake Pharma Co Ltd
Original Assignee
Sunshine Lake Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sunshine Lake Pharma Co Ltd filed Critical Sunshine Lake Pharma Co Ltd
Publication of WO2023036041A1 publication Critical patent/WO2023036041A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Definitions

  • the disclosure belongs to the field of biotechnology, and in particular relates to 4-1BB antibodies and applications thereof. More specifically, the present disclosure relates to murine antibodies capable of specifically recognizing human 4-1BB, humanized antibodies or antigen-binding fragments thereof, pharmaceutical compositions, detection kits and applications thereof.
  • 4-1BB (also known as CD137, TNFRSF9, etc.) is a member of the tumor necrosis factor receptor superfamily (TNFRS). 4-1BB is ubiquitously present in immune cell sublines such as activated natural killer (NK) and natural killer (NKT) cells, regulatory T cells, dendritic cells (DC), stimulated mast cells, differentiating In myeloid cells, monocytes, neutrophils and eosinophils (Wang, 2009, Immunological Reviews 229:192-215), it is involved in the regulation of cell proliferation, differentiation and programmed cell death.
  • NK natural killer
  • NKT natural killer
  • DC dendritic cells
  • stimulated mast cells differentiating In myeloid cells
  • monocytes monocytes
  • neutrophils neutrophils and eosinophils
  • Human 4-1BB is a protein with 255 amino acids.
  • the protein contains a signal sequence at amino acid positions 1-17, followed by an extracellular domain of 169 amino acids, a transmembrane region of 27 amino acids, and an intracellular domain of 42 amino acids (Cheuk ATC et al., 2004, Cancer Gene Therapy, 11:215-226).
  • 4-1BB is expressed on the cell surface as monomers and dimers, and readily trimerizes with ligands for signal transduction.
  • 4-1BB has been reported to be a co-stimulatory receptor for activated T cells, and cross-linking of 4-1BB can enhance T cell proliferation, IL-2 secretion, survival, and cytolytic activity. 4-1BB can also induce proliferation of peripheral monocytes, enhance T cell apoptosis induced by TCR/CD3-triggered activation and regulated CD28 co-stimulation, thereby promoting Th1 cell responses. Its expression is induced by lymphocyte activation, and in addition to the 4-1BB ligand, the TNF receptor-associated factor (TRAF) adapter protein was found to bind to 4-1BB, resulting in the activation of NF- ⁇ B signaling. Specific agonistic antibodies against 4-1BB have been developed and found to enhance T cell function and promote antitumor activity.
  • TNF receptor-associated factor (TRAF) adapter protein was found to bind to 4-1BB, resulting in the activation of NF- ⁇ B signaling.
  • the present disclosure provides a therapeutically applicable and safe antibody specifically binding to 4-1BB or an antigen-binding portion thereof.
  • Antibodies specific for 4-1BB of the present disclosure, or antigen-binding portions thereof are agonistic antibodies against 4-1BB.
  • Agonistic antibodies against 4-1BB show excellent antitumor effects. Accordingly, these agonistic antibodies, or antigen-binding portions thereof, are expected to be effective in the treatment of cancer or autoimmune diseases by modulating the immune response, for example, by modulating the activity of CD4 + cells, CD8 + cells, dendritic cells and/or natural killer cells .
  • the present disclosure relates to isolated antibodies, or antigen-binding portions thereof, that bind to 4-1BB and elicit cellular signaling mediated by 4-1BB.
  • an antibody or antigen-binding portion thereof that specifically binds 4-1BB or a fragment thereof, the antibody or antigen-binding portion thereof comprising a heavy chain variable region and a light chain variable region.
  • the heavy chain variable region includes heavy chain complementarity determining regions HCDR1, HCDR2 and HCDR3, wherein the HCDR1 includes amino acids selected from 1, 7, 13, 19, 25 or 31 sequence or an amino acid sequence in which one or more amino acid residues are replaced by different amino acid residues, for example, an amino acid sequence in which 1 to 4 amino acid residues are replaced by different amino acid residues; the HCDR2 includes selected from such as SEQ ID NO : the amino acid sequence shown in 2, 8, 14, 20, 26 or 32 or an amino acid sequence in which one or more amino acid residues are replaced by different amino acid residues, for example, wherein 1 to 10 amino acid residues are replaced by different amino acid residues The amino acid sequence of residue replacement;
  • the HCDR3 comprises an amino acid sequence selected from the amino acid sequence shown in SEQ ID NO: 3, 9, 15, 21, 27 or 33 or wherein one or more amino acid residues are substituted by different amino acid residues Amino acid sequence, for example, an amino acid sequence in which 1 to 2 amino acid residues
  • the light chain variable region includes light chain complementarity determining regions LCDR1, LCDR2 and LCDR3, wherein the LCDR1 includes a sequence selected from the group consisting of SEQ ID NO: 4, 10, 16, 22, 28 or 34
  • the LCDR1 includes a sequence selected from the group consisting of SEQ ID NO: 4, 10, 16, 22, 28 or 34
  • the amino acid sequence shown or an amino acid sequence in which one or more amino acid residues are replaced by different amino acid residues for example, an amino acid sequence in which 1 to 10 amino acid residues are replaced by different amino acid residues
  • the LCDR2 includes selected From the amino acid sequence shown in SEQ ID NO: 5, 11, 17, 23, 29 or 35 or an amino acid sequence in which one or more amino acid residues are replaced by different amino acid residues, for example, 1 to 6 amino acid residues thereof Amino acid sequence substituted by different amino acid residues
  • said LCDR3 comprises an amino acid sequence selected from amino acid sequences shown in SEQ ID NO: 6, 12, 18, 24, 30 or 36 or wherein one or more amino acid residues are substituted by
  • the antibody may be a bispecific antibody or a multispecific antibody.
  • an antibody or antigen binding portion of the disclosure is capable of binding a different epitope on 4-1BB, or binding an antigen or epitope other than 4-1BB.
  • the heavy chain variable region comprises: comprising the amino acid sequence shown in SEQ ID NO: 1 or wherein one or more (for example, 1 to 4) amino acid residues are different amino acids HCDR1 of an amino acid sequence with residue substitution, including the amino acid sequence shown in SEQ ID NO: 2 or HCDR2 of an amino acid sequence in which one or more (for example, 1 to 10) amino acid residues are substituted by different amino acid residues , and HCDR3 comprising an amino acid sequence as shown in SEQ ID NO: 3 or an amino acid sequence in which one or more (for example, 1 to 2) amino acid residues are substituted by different amino acid residues.
  • the heavy chain variable region comprises: comprising the amino acid sequence shown in SEQ ID NO: 7 or wherein one or more (for example, 1 to 4) amino acid residues are different amino acids HCDR1 of an amino acid sequence substituted by residues, including an amino acid sequence as shown in SEQ ID NO: 8 or HCDR2 of an amino acid sequence in which one or more (for example, 1 to 10) amino acid residues are substituted by different amino acid residues , and HCDR3 comprising an amino acid sequence as shown in SEQ ID NO: 9 or an amino acid sequence in which one or more (for example, 1 to 2) amino acid residues are substituted by different amino acid residues.
  • the heavy chain variable region comprises: comprising the amino acid sequence shown in SEQ ID NO: 13 or wherein one or more (for example, 1 to 4) amino acid residues are different amino acids HCDR1 of an amino acid sequence substituted by residues, including the amino acid sequence shown in SEQ ID NO: 14 or HCDR2 of an amino acid sequence in which one or more (for example, 1 to 10) amino acid residues are substituted by different amino acid residues , and HCDR3 comprising an amino acid sequence as shown in SEQ ID NO: 15 or an amino acid sequence in which one or more (for example, 1 to 2) amino acid residues are substituted by different amino acid residues.
  • the heavy chain variable region comprises: comprising the amino acid sequence shown in SEQ ID NO: 19 or wherein one or more (for example, 1 to 4) amino acid residues are different amino acids HCDR1 of an amino acid sequence substituted by residues, including an amino acid sequence as shown in SEQ ID NO: 20 or HCDR2 of an amino acid sequence in which one or more (for example, 1 to 10) amino acid residues are substituted by different amino acid residues , and HCDR3 comprising an amino acid sequence as shown in SEQ ID NO: 21 or an amino acid sequence in which one or more (for example, 1 to 2) amino acid residues are substituted by different amino acid residues.
  • the heavy chain variable region comprises: comprising the amino acid sequence shown in SEQ ID NO: 25 or wherein one or more (for example, 1 to 4) amino acid residues are different amino acids HCDR1 of an amino acid sequence substituted by residues, including an amino acid sequence as shown in SEQ ID NO: 26 or HCDR2 of an amino acid sequence in which one or more (for example, 1 to 10) amino acid residues are substituted by different amino acid residues , and HCDR3 comprising an amino acid sequence as shown in SEQ ID NO: 27 or an amino acid sequence in which one or more (for example, 1 to 2) amino acid residues are substituted by different amino acid residues.
  • the heavy chain variable region comprises: comprising the amino acid sequence shown in SEQ ID NO: 31 or wherein one or more (for example, 1 to 4) amino acid residues are different amino acids HCDR1 of an amino acid sequence substituted by residues, including an amino acid sequence as shown in SEQ ID NO: 32 or HCDR2 of an amino acid sequence in which one or more (for example, 1 to 10) amino acid residues are substituted by different amino acid residues , and HCDR3 comprising an amino acid sequence as shown in SEQ ID NO: 33 or an amino acid sequence in which one or more (for example, 1 to 2) amino acid residues are substituted by different amino acid residues.
  • the light chain variable region includes: comprising the amino acid sequence shown in SEQ ID NO: 4 or wherein one or more (for example, 1 to 4) amino acid residues are different amino acids LCDR1 of an amino acid sequence substituted by residues, including an amino acid sequence as shown in SEQ ID NO: 5 or LCDR2 of an amino acid sequence in which one or more (for example, 1 to 6) amino acid residues are substituted by different amino acid residues , comprising an amino acid sequence as shown in SEQ ID NO: 6 or an LCDR3 of an amino acid sequence in which one or more (for example, 1 to 8) amino acid residues are substituted by different amino acid residues.
  • the light chain variable region includes: comprising the amino acid sequence shown in SEQ ID NO: 10 or wherein one or more (for example, 1 to 4) amino acid residues are different amino acids LCDR1 of an amino acid sequence substituted by residues, including LCDR2 of an amino acid sequence as shown in SEQ ID NO: 11 or an amino acid sequence in which one or more (for example, 1 to 6) amino acid residues are substituted by different amino acid residues , comprising the amino acid sequence shown in SEQ ID NO: 12 or the LCDR3 of an amino acid sequence in which one or more (for example, 1 to 8) amino acid residues are substituted by different amino acid residues.
  • the light chain variable region includes: comprising the amino acid sequence shown in SEQ ID NO: 16 or wherein one or more (for example, 1 to 4) amino acid residues are different amino acids LCDR1 of an amino acid sequence substituted by residues, including an amino acid sequence as shown in SEQ ID NO: 17 or LCDR2 of an amino acid sequence wherein one or more (for example, 1 to 6) amino acid residues are substituted by different amino acid residues , comprising the amino acid sequence shown in SEQ ID NO: 18 or the LCDR3 of an amino acid sequence in which one or more (for example, 1 to 8) amino acid residues are substituted by different amino acid residues.
  • the light chain variable region includes: comprising the amino acid sequence shown in SEQ ID NO: 22 or wherein one or more (for example, 1 to 4) amino acid residues are different amino acids LCDR1 of an amino acid sequence substituted by residues, including the amino acid sequence shown in SEQ ID NO: 23 or LCDR2 of an amino acid sequence in which one or more (for example, 1 to 6) amino acid residues are substituted by different amino acid residues , comprising an amino acid sequence as shown in SEQ ID NO: 24 or an LCDR3 of an amino acid sequence in which one or more (for example, 1 to 8) amino acid residues are substituted by different amino acid residues.
  • the light chain variable region includes: comprising the amino acid sequence shown in SEQ ID NO: 28 or wherein one or more (for example, 1 to 4) amino acid residues are different amino acids LCDR1 of an amino acid sequence substituted by residues, including an amino acid sequence as shown in SEQ ID NO: 29 or LCDR2 of an amino acid sequence in which one or more (for example, 1 to 6) amino acid residues are substituted by different amino acid residues , comprising an amino acid sequence as shown in SEQ ID NO: 30 or an LCDR3 of an amino acid sequence in which one or more (for example, 1 to 8) amino acid residues are substituted by different amino acid residues.
  • the light chain variable region includes: comprising the amino acid sequence shown in SEQ ID NO: 34 or wherein one or more (for example, 1 to 4) amino acid residues are different amino acids LCDR1 of an amino acid sequence substituted by residues, including LCDR2 of an amino acid sequence as shown in SEQ ID NO: 35 or an amino acid sequence in which one or more (for example, 1 to 6) amino acid residues are substituted by different amino acid residues , comprising an amino acid sequence as shown in SEQ ID NO: 36 or an LCDR3 of an amino acid sequence in which one or more (for example, 1 to 8) amino acid residues are substituted by different amino acid residues.
  • the heavy chain variable region comprises an amino acid sequence as shown in SEQ ID NO: 37, 39, 41, 43, 45 or 47 or an amino acid wherein one or more amino acid residues are different Amino acid sequence of residue substitutions.
  • the light chain variable region comprises an amino acid sequence as shown in SEQ ID NO: 38, 40, 42, 44, 46 or 48 or an amino acid wherein one or more amino acid residues are different Amino acid sequence of residue substitutions.
  • the heavy chain of the above-mentioned antibody or its antigen-binding portion comprising the amino acid sequence shown in SEQ ID NO: 37 or an amino acid sequence in which one or more amino acid residues are replaced by different amino acid residues may be Variable region, and the light chain variable region of the amino acid sequence shown in SEQ ID NO: 38 or wherein one or more amino acid residues are substituted by different amino acid residues.
  • the heavy chain of the above-mentioned antibody or its antigen-binding portion comprising the amino acid sequence shown in SEQ ID NO: 39 or an amino acid sequence in which one or more amino acid residues are substituted by different amino acid residues may be Variable region, and the light chain variable region of the amino acid sequence shown in SEQ ID NO: 40 or wherein one or more amino acid residues are substituted by different amino acid residues.
  • the heavy chain of the above-mentioned antibody or its antigen-binding portion comprising the amino acid sequence shown in SEQ ID NO: 41 or an amino acid sequence in which one or more amino acid residues are replaced by different amino acid residues may be Variable region, and the light chain variable region of the amino acid sequence shown in SEQ ID NO: 42 or wherein one or more amino acid residues are replaced by different amino acid residues.
  • the heavy chain of the above-mentioned antibody or its antigen-binding portion comprising the amino acid sequence shown in SEQ ID NO: 43 or an amino acid sequence in which one or more amino acid residues are replaced by different amino acid residues may be Variable region, and the light chain variable region of the amino acid sequence shown in SEQ ID NO: 44 or wherein one or more amino acid residues are substituted by different amino acid residues.
  • the heavy chain of the above-mentioned antibody or its antigen-binding portion comprising the amino acid sequence shown in SEQ ID NO: 45 or an amino acid sequence in which one or more amino acid residues are replaced by different amino acid residues may be Variable region, and the light chain variable region of the amino acid sequence shown in SEQ ID NO: 46 or wherein one or more amino acid residues are substituted by different amino acid residues.
  • the heavy chain of the above-mentioned antibody or its antigen-binding portion comprising the amino acid sequence shown in SEQ ID NO: 47 or an amino acid sequence in which one or more amino acid residues are replaced by different amino acid residues may be Variable region, and the light chain variable region of the amino acid sequence shown in SEQ ID NO: 48 or wherein one or more amino acid residues are substituted by different amino acid residues.
  • the above-mentioned antibody comprises an amino acid sequence as shown in SEQ ID NO: 49 or a heavy chain of an amino acid sequence in which one or more amino acid residues are substituted by different amino acid residues, and such as SEQ ID NO : The light chain of the amino acid sequence shown in 50 or the amino acid sequence wherein one or more amino acid residues are replaced by different amino acid residues.
  • the above-mentioned antibody comprises an amino acid sequence as shown in SEQ ID NO: 51 or a heavy chain of an amino acid sequence in which one or more amino acid residues are substituted by different amino acid residues, and such as SEQ ID NO : light chain of the amino acid sequence shown in 52 or an amino acid sequence in which one or more amino acid residues are substituted by different amino acid residues.
  • the above-mentioned antibody comprises an amino acid sequence as shown in SEQ ID NO: 53 or a heavy chain of an amino acid sequence in which one or more amino acid residues are substituted by different amino acid residues, and the amino acid sequence as shown in SEQ ID NO: The light chain of the amino acid sequence shown in :54 or the amino acid sequence wherein one or more amino acid residues are replaced by different amino acid residues.
  • the above-mentioned antibody comprises an amino acid sequence as shown in SEQ ID NO: 55 or a heavy chain of an amino acid sequence in which one or more amino acid residues are substituted by different amino acid residues, and the amino acid sequence as shown in SEQ ID NO: The light chain of the amino acid sequence shown in :56 or the amino acid sequence wherein one or more amino acid residues are replaced by different amino acid residues.
  • the above-mentioned antibody comprises an amino acid sequence as shown in SEQ ID NO: 57 or a heavy chain of an amino acid sequence in which one or more amino acid residues are substituted by different amino acid residues, and the amino acid sequence as shown in SEQ ID NO: The amino acid sequence shown in :58 or the light chain of the amino acid sequence wherein one or more amino acid residues are substituted by different amino acid residues.
  • the above-mentioned antibody comprises an amino acid sequence as shown in SEQ ID NO: 59 or a heavy chain of an amino acid sequence in which one or more amino acid residues are substituted by different amino acid residues, and the amino acid sequence as shown in SEQ ID NO: : light chain of the amino acid sequence shown in 60 or an amino acid sequence wherein one or more amino acid residues are substituted by different amino acid residues.
  • a humanized antibody or antigen-binding portion thereof derived from the above-mentioned antibody or antigen-binding portion thereof.
  • the antibody or antigen-binding portion thereof comprises a heavy chain variable region and a light chain variable region.
  • the heavy chain variable region includes heavy chain complementarity determining regions HCDR1, HCDR2 and HCDR3;
  • the HCDR1 has an amino acid sequence represented by SYWX 1 X 2 , wherein X 1 is selected from isoleucine acid, methionine or valine, X 2 is selected from asparagine, histidine or threonine;
  • the HCDR2 has an amino acid sequence shown by X 3 IYPSDTYTX 4 YX 5 QKFQX 6 , wherein X 3 is selected from From asparagine or isoleucine, X4 is selected from asparagine, aspartic acid or serine, X5 is selected from asparagine or alanine, X6 is selected from aspartic acid or glycine;
  • HCDR3 has the amino acid sequence shown in SEQ ID NO: 71 or an amino acid sequence in which one or more amino acid residues are replaced with different amino acid residues.
  • the HCDR1 has the amino acid sequence shown in SEQ ID NO: 7, 61, 62 or 63; the HCDR2 has the amino acid sequence shown in SEQ ID NO: 64, 65, 66, 67, 68, 69 Or the amino acid sequence shown in 70; The HCDR3 has the amino acid sequence shown in SEQ ID NO:71.
  • the above-mentioned heavy chain variable region also includes a framework region (FR);
  • the framework region (H-FR) of the heavy chain variable region may include, comprising SEQ ID NO: 79 or 80 shown Amino acid sequence or H-FR1 of an amino acid sequence in which one or more (for example, 1 to 6) amino acid sequences are substituted, comprising the amino acid sequence shown in any one of SEQ ID NO: 81 to 84 or one or more of them H-FR2 of an amino acid sequence substituted by amino acid sequences (for example, 1 to 5), including the amino acid sequence shown in any one of SEQ ID NO: 85 to 89 or one or more of them (for example, 1 to 12 A) H-FR3 of an amino acid sequence whose amino acid sequence is substituted, and an amino acid sequence comprising the amino acid sequence shown in SEQ ID NO: 90 or 91 or one or more (for example, 1 to 3) amino acid sequences are substituted
  • the H-FR4 comprising SEQ ID NO: 79 or 80 shown Amino acid
  • the heavy chain variable region has an amino acid sequence as shown in any one of SEQ ID NO: 132-138 or an amino acid sequence in which one or more amino acid sequences are substituted.
  • the light chain variable region includes light chain complementarity determining regions LCDR1, LCDR2 and LCDR3;
  • the LCDR1 has an amino acid sequence as shown in SEQ ID NO: 10 or one or more thereof (for example , 1 to 10) amino acid residues are replaced by different amino acid residues;
  • the LCDR2 has an amino acid sequence as shown in SEQ ID NO: 11 or one or more (for example, 1 to 6) amino acids Amino acid sequence in which residues are replaced by different amino acid residues;
  • the LCDR3 has the amino acid sequence shown in SEQ ID NO: 12 or one or more (for example, 1 to 8) amino acid residues are replaced by different amino acid residues Substituted amino acid sequences.
  • the above-mentioned light chain variable region also includes a framework region (FR);
  • the framework region (L-FR) of the light chain variable region may include, comprising SEQ ID NO: 92 or 93 shown in Amino acid sequence or L-FR1 in which one or more (for example, 1 to 5) amino acid sequences are substituted amino acid sequences; containing the amino acid sequence shown in any one of SEQ ID NO: 94 to 98 or one or L-FR2 of an amino acid sequence in which multiple (for example, 1 to 5) amino acid sequences are substituted; containing the amino acid sequence shown in any one of SEQ ID NO: 99 to 102 or one or more of them (for example, 1 to 5) 7) the L-FR3 of the amino acid sequence whose amino acid sequence is substituted; and the amino acid sequence containing the amino acid sequence shown in SEQ ID NO: 103 or 104 or one or more (for example, 1 to 3) amino acid sequences are substituted Sequence of L-FR4.
  • the light chain variable region has an amino acid sequence as shown in any one of SEQ ID NO: 139-144 or an amino acid sequence in which one or more amino acid sequences are substituted.
  • the antibody or antigen-binding portion thereof is a heavy chain variable region having an amino acid sequence as shown in any one of SEQ ID NO: 132-138, and having a sequence as shown in SEQ ID NO: 139 Any combination of the light chain variable regions of the amino acid sequences shown in any one of ⁇ 144.
  • the antibody or antigen-binding portion thereof is a murine antibody, a human antibody, a primate antibody, preferably a murine antibody or a human antibody.
  • the humanized antibody comprises an amino acid sequence as shown in SEQ ID NO: 145 or a heavy chain constant region of an amino acid sequence in which one or more amino acids are substituted, and the amino acid sequence as shown in SEQ ID NO: 146 The light chain constant region of the amino acid sequence shown or an amino acid sequence in which one or more amino acids are substituted.
  • an antibody or antigen-binding portion thereof comprising a heavy chain variable region and a light chain variable region.
  • the heavy chain variable region includes heavy chain complementarity determining regions HCDR1, HCDR2 and HCDR3;
  • the HCDR1 has the amino acid sequence shown by SYDIS or one or more of them (for example, 1 to 4 each) an amino acid sequence in which the amino acid residues are replaced by different amino acid residues;
  • the HCDR2 has the amino acid sequence shown by VIWTGZ 1 GTNYZ 2 Z 3 Z 4 FZ 5 S, wherein Z 1 is selected from glycine or serine, and Z 2 is selected from From asparagine or alanine, Z3 is selected from serine or proline, Z4 is selected from threonine or proline, Z5 is selected from methionine or lysine;
  • the HCDR3 has VDY The amino acid sequence shown or an amino acid sequence in which one or more (for example
  • the HCDR1 has an amino acid sequence as shown in SEQ ID NO: 13 or an amino acid sequence in which one or more amino acid sequences are substituted;
  • the HCDR2 has an amino acid sequence such as SEQ ID NO: 72, 73 or The amino acid sequence shown in 74, or the amino acid sequence in which one or more amino acid sequences are substituted;
  • the HCDR3 has the amino acid sequence shown in SEQ ID NO: 15, or the amino acid sequence in which one or more amino acid sequences are substituted .
  • the heavy chain variable region further includes a framework region (FR);
  • the framework region (H-FR) of the heavy chain variable region includes: any one of SEQ ID NO: 105-108 H-FR1 of the amino acid sequence shown or an amino acid sequence in which one or more amino acid sequences are substituted; H-FR1 containing the amino acid sequence shown in SEQ ID NO: 109 or 110 or an amino acid sequence in which one or more amino acid sequences are substituted H-FR2; H-FR3 containing the amino acid sequence shown in any one of SEQ ID NO: 111 to 116 or an amino acid sequence in which one or more amino acid sequences are substituted; and containing SEQ ID NO: 117 or 118 The amino acid sequence of or the H-FR4 of the amino acid sequence in which one or more amino acid sequences are substituted.
  • the heavy chain variable region has an amino acid sequence as shown in any one of SEQ ID NO: 147-152 or an amino acid sequence in which one or more amino acid sequences are substituted.
  • the light chain variable region includes light chain complementarity determining regions LCDR1, LCDR2 and LCDR3;
  • the LCDR1 has the amino acid sequence shown by RSSQZ 6 LVHSNTNTYLH, wherein Z 6 is selected from serine or threonine acid;
  • the LCDR2 has an amino acid sequence as shown in SEQ ID NO:77 or an amino acid sequence in which one or more amino acid residues are substituted by different amino acid residues;
  • the LCDR3 has an amino acid sequence shown by SQZ 7 THVPWT , wherein Z 7 is selected from serine or threonine.
  • the LCDR1 has an amino acid sequence as shown in SEQ ID NO: 75 or 76, wherein one or more amino acid sequences are substituted amino acid sequences;
  • the LCDR2 has an amino acid sequence as shown in SEQ ID NO: 77 The amino acid sequence shown, wherein one or more amino acid sequences are substituted amino acid sequences;
  • the LCDR3 has an amino acid sequence as shown in SEQ ID NO: 18 or 78, wherein one or more amino acid sequences are substituted amino acid sequences.
  • the above-mentioned light chain variable region also includes the following framework region (FR); the framework region (L-FR) of the light chain variable region includes any of SEQ ID NO: 119-122
  • the light chain variable region has an amino acid sequence as shown in any one of SEQ ID NO: 153-157 or an amino acid sequence in which one or more amino acid sequences are substituted.
  • the antibody or its antigen-binding portion is a heavy chain variable region having an amino acid sequence as shown in any one of SEQ ID NO: 147-152, and having a sequence as shown in SEQ ID NO: 153 Any combination of the light chain variable regions of the amino acid sequences shown in any one of ⁇ 157.
  • the heavy chain variable region of the amino acid sequence shown in any one of SEQ ID NO:147 ⁇ 152, and the amino acid sequence shown in any one of SEQ ID NO:153 ⁇ 157 is a humanized variable region sequence.
  • the disclosed antibody or antigen-binding portion thereof is a murine antibody, a human antibody, a primate antibody, preferably a murine antibody or a human antibody.
  • the humanized antibody comprises an amino acid sequence as shown in SEQ ID NO: 158 or a heavy chain constant region of an amino acid sequence in which one or more amino acids are substituted, and the amino acid sequence as shown in SEQ ID NO: 159 The light chain constant region of the amino acid sequence shown or an amino acid sequence in which one or more amino acids are substituted.
  • the disclosed antibody or antigen-binding portion thereof cross-reacts with at least one 4-1BB from the group consisting of cynomolgus monkey, mouse, rat, dog and/or human.
  • the disclosed antibodies are selected from IgG1, IgG2, IgG3, IgG4, IgM, IgA1, IgA2, IgD or IgE antibodies, preferably IgG1 or IgG4 antibodies.
  • nucleic acid molecule encoding the above-mentioned antibody of the present disclosure or an antigen-binding portion thereof.
  • an expression vector which includes the above-mentioned nucleic acid molecule.
  • a cell transfected with the above-mentioned expression vector of the present disclosure is provided.
  • a pharmaceutical composition comprising the above-mentioned antibody or its antigen-binding portion as disclosed herein, the above-mentioned nucleic acid molecule as disclosed herein, the above-mentioned expression vector as disclosed herein or The above cells as disclosed in the present disclosure, and a pharmaceutically acceptable carrier.
  • a method for inducing or enhancing cytokine production of immune cells in a subject comprising administering to a subject in need an effective amount of the above-mentioned An antibody or an antigen-binding portion thereof, or the above-mentioned pharmaceutical composition of the present disclosure.
  • the cytokine is IL-2, TNF- ⁇ , IL-13, IFN- ⁇ or a combination thereof.
  • the cytokines are produced in the tumor microenvironment.
  • a method of treating cancer comprising administering to a subject in need an effective amount of the above-mentioned antibody of the present disclosure or an antigen-binding portion thereof, or the above-mentioned antibody of the present disclosure.
  • pharmaceutical composition comprising administering to a subject in need an effective amount of the above-mentioned antibody of the present disclosure or an antigen-binding portion thereof, or the above-mentioned antibody of the present disclosure.
  • the cancer is selected from melanoma, glioma, kidney cancer, breast cancer, blood cancer, and head and neck cancer.
  • the cancer is hematological cancer, such as B-cell lymphoma.
  • the above-mentioned antibody or its antigen-binding portion of the present disclosure there is provided the above-mentioned nucleic acid molecule of the present disclosure, the above-mentioned expression vector of the present disclosure, the above-mentioned cells of the present disclosure, or the above-mentioned pharmaceutical composition of the present disclosure, in Application in the preparation of medicines for treating cancer.
  • the cancer is selected from the group consisting of melanoma, glioma, colon adenocarcinoma, pancreatic cancer, colon cancer, gastrointestinal cancer, prostate cancer, bladder cancer, ovarian cancer, lung cancer, renal cell carcinoma, Nasopharyngeal cancer, kidney cancer, breast cancer, blood cancer and head and neck cancer.
  • Figure 1 shows the binding of antibodies according to some embodiments of the present disclosure to a CHO cell line highly expressing human 4-1BB.
  • Figure 2 shows the binding of antibodies according to some embodiments of the present disclosure to monkey-derived 4-1BB recombinant protein.
  • Figure 3 shows the binding of antibodies to activated T cells according to some embodiments of the present disclosure.
  • Figure 4 shows a T cell secretion IL2 indicator assay for agonist activity of antibodies according to some embodiments of the present disclosure.
  • FIG. 5 shows an indicator of T cell secretion of IFN- ⁇ to measure the agonist activity of antibodies according to some embodiments of the present disclosure.
  • FIG. 6 shows the binding ability of humanized antibodies according to some embodiments of the present disclosure to a CHO cell line highly expressing human 4-1BB.
  • Figure 7 shows the anti-tumor activity of humanized antibodies according to some embodiments of the present disclosure.
  • Figure 8 shows the antitumor activity of humanized antibody HEC512119.
  • amino acid refers to naturally occurring and synthetic amino acids, as well as amino acid analogs and amino acid mimetics that function in a similar manner to naturally occurring amino acids.
  • Naturally occurring amino acids are those encoded by the genetic code, as well as modified amino acids such as hydroxyproline, gamma-carboxyglutamate, and O-phosphoserine.
  • Amino acid analogs are compounds that have the same basic chemical structure as naturally occurring amino acids, i.e., carbons bonded to hydrogen, carboxyl, amino and R groups, such as homoserine, norleucine, methionine sulfoxide, Methylsulfonium methionine.
  • Amino acid mimetics are compounds that differ structurally from the general chemical structure of amino acids, but function in a manner similar to naturally occurring amino acids.
  • polar amino acid refers to an amino acid comprising a side chain that prefers to reside in an aqueous environment.
  • the polar amino acid is selected from arginine, asparagine, aspartic acid, glutamic acid, glutamine, histidine, lysine, serine, threonine, and tyrosine.
  • Polar amino acids can be positively charged, negatively charged, or neutrally charged.
  • non-polar amino acid is selected from the group consisting of alanine, cysteine, glycine, isoleucine, leucine, methionine, phenylalanine, proline, tryptophan acid and valine.
  • substitution with one or more different amino acids means that at least one existing amino acid residue in a predetermined amino acid sequence (the amino acid sequence of the starting polypeptide) is replaced by another different “replacement” amino acid residue .
  • Amino acid insertion refers to the incorporation of at least one additional amino acid into a predetermined amino acid sequence. While inserts typically consist of insertions of 1 or 2 amino acid residues, larger “peptide insertions” can also be made, for example insertions of about 3 to 5 or even up to about 10, 15 or 20 amino acid residues. As disclosed above, the inserted residues may be naturally occurring or non-naturally occurring.
  • Amin deletion refers to the removal of at least one amino acid residue from a predetermined amino acid sequence.
  • Antibodies suitable for use in the present disclosure may comprise conservative amino acid substitutions at one or more amino acid residues, eg, at essential or non-essential amino acid residues.
  • a "conservative amino acid substitution” is an amino acid substitution in which an amino acid residue is replaced by an amino acid residue having a similar side chain.
  • Families of amino acid residues with similar side chains have been defined in the art, including basic side chains (e.g., lysine, arginine, histidine), acidic side chains (e.g., aspartic acid, glutamic acid) , uncharged polar side chains (such as glycine, asparagine, glutamine, serine, threonine, tyrosine, cysteine), nonpolar side chains (such as alanine, valine , leucine, isoleucine, proline, phenylalanine, methionine, tryptophan), ⁇ -branched side chains (e.g.
  • basic side chains e.g., lysine, arginine, histidine
  • acidic side chains e.g., aspartic acid, glutamic acid
  • uncharged polar side chains such as glycine, asparagine, glutamine, serine, threonine, tyrosine, cysteine
  • an essential or nonessential amino acid residue in an antibody is preferably replaced with another amino acid residue from the same side chain family.
  • amino acid stretches may be replaced with structurally similar stretches that differ in the order and/or composition of side chain family members.
  • mutations may be introduced randomly along all or part of the coding sequence, such as by saturation mutagenesis, and the resulting mutants may be incorporated into the binding polypeptides of the invention and directed against these binding polypeptides The ability to bind to the desired target is screened.
  • anti-4-1BB agonistic antibody or “specific agonistic antibody against 4-1BB” means that it specifically binds to 4-1BB and partially or completely promotes, induces, increases and/or activates Antibodies to 4-1BB biological activity, responses and/or downstream pathways mediated by 4-1BB signaling or other 4-1BB mediated functions.
  • Tumor necrosis factor receptor (TNFR) signaling particularly TNFRSF activation, requires receptor clustering and multimerization.
  • 4-1BB is one of the TNFSF receptors known to require clustering to trigger downstream signaling. Formation of 2 or more trimers by cross-linking of 4-1BB has been reported to result in a stronger activated protein.
  • the anti-4-1BB agonistic antibody binds 4-1BB and induces multimerization of 4-1BB into 2 or more trimers.
  • the terms “specifically bind”, “selectively bind”, “selectively bind” and “specifically bind” as used herein refer to the binding of an antibody or antigen-binding portion thereof to an epitope on a predetermined antigen.
  • the antibody is present at about less than 10 ⁇ 6 M, such as about less than 10 -7 M, 10 ⁇ 8 M, 10 ⁇ 9 M or 10 ⁇ 10 M or even lower equilibrium dissociation constant (K D ) binding
  • binding to the predetermined antigen affinity is binding to other than the predetermined antigen or closely related At least twice the affinity of non-specific antigens (such as BSA, casein) outside the antigen.
  • subject as used herein includes any human or non-human animal.
  • methods and compositions of the invention can be used to treat a subject with cancer.
  • non-human animal includes all vertebrates, such as mammals and non-mammals, such as non-human primates, sheep, dogs, cows, chickens, amphibians, reptiles, and the like.
  • antibody fragment refers to fragments of an antibody that retain binding to a target antigen (eg, 4-1BB) and have the same activity as the full-length antibody.
  • target antigen eg, 4-1BB
  • fragments include, for example, single chain antibodies, single chain Fv fragments (scFv), Fd fragments, Fab fragments, Fab' fragments or F(ab')2 fragments.
  • scFv fragment is a single polypeptide chain that includes the heavy and light chain variable regions of the antibody from which the scFv is derived.
  • intrabodies, minibodies, tribodies and diabodies are included within the definition of antibody and are suitable for use in the methods described herein. See eg Todorovska et al. (2001), J. Immunol. Methods, 248(1): 47-66; Hudson and Kortt, (1999), J. Immunol. Methods, 231(1): 177-189; Poljak, ( 1994), Structure, 2(12):1121-1123; Rondon and Marasco, (1997), Annu.Rev.Microbiol., 51:257-283, the respective disclosures of which are incorporated herein by reference in their entirety middle.
  • the percent identity between two nucleotide sequences can be determined using the GAP program in the GCG software package (available from http://www.gcg.com), using the NWSgapdna.CMP matrix and gap weights 40, 50, 60, 70 or 80 and length weight 1, 2, 3, 4, 5 or 6 determination.
  • the percent identity between two nucleotide or amino acid sequences can also be calculated using the algorithm of E. Meyers and W.
  • the algorithm has been incorporated into the ALIGN program (version 2.0).
  • the percent identity between two amino acid sequences can be determined using the algorithm of Needleman and Wunsch (J. Mol. Biol. (48):444-453 (1970) ), using the Blossum 62 matrix or the PAM250 matrix, and a gap weight of 16, 14, 12, 10, 8, 6, or 4 and length weights 1, 2, 3, 4, 5, or 6 determined, the algorithm has been incorporated into the GCG software package (available from http://www.gcg.com ) in the GAP program.
  • tumor microenvironment refers to the cellular environment or microenvironment in which tumors or neoplasms reside, including surrounding blood vessels and non-cancerous cells, including but not limited to immune cells, fibroblasts, myeloid-derived inflammatory cells and lymphocytes. Tumors and the surrounding microenvironment are closely related and constantly interact. Tumors can affect the microenvironment by releasing extracellular signals, promoting tumor angiogenesis and inducing peripheral immune tolerance, and immune cells in the microenvironment can affect the growth and evolution of tumor cells.
  • Human 4-1BB is a transmembrane polypeptide with 255 amino acids (Accession No. NM_001561; NP_001552), which is a member of the phylogenetically conserved tumor necrosis factor receptor (TNFR) superfamily. 4-1BB and its ligands are involved in the regulation of many immune activities. The 4-1BB ligand crosslinks its receptor 4-1BB expressed on activated T cells and co-stimulates T cell activity. 4-1BB is an activation-induced co-stimulatory molecule.
  • variable region or “variable domain” as used herein refers to the domain of an antibody heavy or light chain that participates in the binding of an antigen-binding molecule to an antigen.
  • the variable domains (VH and VL, respectively) of the heavy and light chains of native antibodies generally have similar structures, with each domain comprising four conserved framework regions (FRs) and three hypervariable regions (HVRs). A single VH or VL domain may be sufficient to confer antigen binding specificity.
  • variable means that certain segments of the variable domains generally differ in sequence among antibodies.
  • the V domain mediates antigen binding and defines the specificity of a particular antibody for its particular antigen.
  • variability is not evenly distributed across the variable domain. Instead, it is concentrated in three segments called hypervariable regions (HVRs) within the light and heavy chain variable domains.
  • HVRs hypervariable regions
  • FR framework regions
  • the variable domains of native heavy and light chains each comprise four FR regions, mostly in a ⁇ -sheet configuration, connected by three HVRs that form loops connecting and in some cases forming part of the ⁇ -sheet structure.
  • the HVRs in each chain are held tightly together by the FR regions and, together with the HVRs of the other chains, contribute to the formation of the antibody's antigen-binding site (see Kabat et al., Sequences of Immunological Interest, 5th ed., National Institute of Health, Bethesda , MD (1991)).
  • the constant domain is not directly involved in the binding of the antibody to the antigen, but has other effector functions, such as participating in the antibody-dependent cellular cytotoxicity of the antibody.
  • hypervariable region refers to the region of an antibody variable domain region that is hypervariable in sequence and/or forms structurally defined loops ("hypervariable loops").
  • native four-chain antibodies contain six HVRs: three in the VH (H1, H2, H3) and three in the VL (L1, L2, L3).
  • HVRs typically comprise amino acid residues from hypervariable loops and/or from "complementarity determining regions (CDRs)", which have the highest sequence variability and/or are involved in antigen recognition.
  • CDRs complementarity determining regions
  • Exemplary CDRs are located at amino acid residues L26-L32(L1), L50-L52(L2), L91-L96(L3), H26-H32( H1), H52-H56 (H2) and H96-H101 (H3) (Chothia et al., J. Mol. Biol. 196:901-917 (1987)).
  • Exemplary CDRs are located at amino acid residues L24-L34(L1), L50-L56(L2), L89-L97(L3), H31-H35( H1), H50-H65 (H2) and H95-H102 (H3) (Kabat et al., Sequences of Proteins of Immunological Interest, 5th Edition, Public Health Service, National Institutes of Health, Bethesda, MD (1991)).
  • exemplary CDRs are located at amino acid residues L27-L32(L1), L50-L51(L2), L89-L97(L3), H26-H33(H1) , H51-H56(H2) and H93-H102(H3) (Honjo, T. and Alt, FW (1995) Immunoglobulin genes. Academic Press pp. 3-443).
  • Table 1 are listed the corresponding amino acid residues comprising the CDRs defined in the references cited above.
  • CDR of an antibody can be defined in various ways, such as the Kabat definition rule based on sequence variability, the Chothia definition rule based on the position of the structural loop region, and antibody humanization based on CDR grafting A reference tool for design (see J Mol Biol 273:927-48, 1997).
  • FR Framework or "FR” as used herein refers to variable domain residues other than hypervariable region (HVR) residues.
  • the FRs of a variable domain typically consist of the following four FR domains: FR1, FR2, FR3 and FR4.
  • HVR and FR sequences typically occur in VH (or VL) in the following sequence: FR1-H1(L1)-FR2-H2(L2)-FR3-H3(L3)-FR4.
  • the "class" of an antibody as used herein refers to the type of constant domain or constant region that the heavy chain of the antibody has.
  • the heavy-chain constant domains that correspond to the different classes of immunoglobulins are called alpha, delta, epsilon, gamma, and mu, respectively.
  • humanized antibody used herein comprises the amino acid residues from the non-human hypervariable region (HVR) and the constant regions of the heavy chain and light chain from the human antibody spliced to obtain the complete sequence of the humanized antibody.
  • a humanized antibody comprises at least one, usually two, variable domains in which all or substantially all of the HVRs (e.g., CDRs) correspond to those of a non-human antibody, and all or substantially all of the FRs Corresponds to FRs of human antibodies.
  • a humanized antibody optionally can comprise at least a portion of an antibody constant region derived from a human antibody.
  • a "humanized form" of an antibody, eg, a non-human antibody refers to an antibody that has been humanized.
  • cross-reactivity refers to the ability of an antibody of the present disclosure to bind 4-1BB from a different species.
  • an antibody of the disclosure may bind human 4-1BB while also binding 4-1BB of another species (eg, mouse, rat, cynomolgus monkey, or dog).
  • cross-reactivity is measured by detecting specific reactivity with purified antigen in a binding assay (eg, SPR, ELISA), or with physiologically expressed cells that bind or otherwise functionally interact.
  • sequence identity with a sequence compared to that sequence means at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with the sequence.
  • nucleic acid sequence can be directly or indirectly connected to the regulatory elements on the carrier, as long as these regulatory elements It is sufficient that the element can regulate the translation and expression of the nucleic acid molecule.
  • regulatory elements may come directly from the vector itself, or be exogenous, that is, not from the vector itself. That is, a nucleic acid molecule is operably linked to a regulatory element.
  • operably linked refers to linking the exogenous gene to the carrier, so that the regulatory elements in the carrier, such as transcriptional regulatory sequences and translational regulatory sequences, etc., can play their intended role in regulating the transcription and translation of the exogenous gene function.
  • the polynucleotides used to encode the heavy chain and light chain of the antibody can be independently inserted into different vectors, usually inserted into the same vector.
  • Commonly used vectors can be, for example, plasmids, phages and the like.
  • the "cell” or “recombinant cell” used herein may contain an expression vector.
  • Expression vectors can be introduced into mammalian cells to obtain recombinant cells, which are then used to express the antibodies or antigen-binding portions provided in the present disclosure.
  • the corresponding antibody can be obtained by culturing the recombinant cells.
  • These usable mammalian cells are, for example, CHO cells and the like.
  • pharmaceutically acceptable carrier may include any solvents, dispersion media, coatings, antibacterial agents, antifungal agents, isotonic and absorption delaying agents and the like that are physiologically compatible. Specific examples may be one or more of water, saline, phosphate-buffered saline, glucose, glycerol, ethanol, etc., and combinations thereof.
  • the pharmaceutical composition may contain isotonic agents, such as sugars, polyalcohols (such as mannitol, sorbitol) or sodium chloride, etc.
  • pharmaceutically acceptable carriers may also include minor amounts of auxiliary substances, such as wetting or emulsifying agents, preservatives or buffers, to prolong the shelf life or potency of the antibody.
  • an antibody of the disclosure, or an antigen-binding portion thereof can be incorporated into a pharmaceutical composition suitable for parenteral administration (eg, intravenous, subcutaneous, intraperitoneal, intramuscular).
  • parenteral administration eg, intravenous, subcutaneous, intraperitoneal, intramuscular.
  • These pharmaceutical compositions can be prepared in various forms, such as liquid, semi-solid and solid dosage forms, etc., including but not limited to liquid solutions (such as injection solutions and infusion solutions), dispersions or suspensions, tablets, pills, Powders, liposomes and suppositories.
  • Typical pharmaceutical compositions are in the form of solutions for injection or infusion.
  • Antibodies of the disclosure, or antigen-binding portions thereof can be administered by intravenous infusion, injection, intramuscular or subcutaneous injection.
  • lymphoma As used herein, the term "cancer of the blood” includes lymphoma, leukemia, myeloma or lymphoid malignancies, as well as cancers of the spleen and lymph nodes.
  • Exemplary lymphomas include B-cell lymphoma (B-cell blood cancer) and T-cell lymphoma.
  • B-cell lymphomas include Hodgkin's lymphoma and most non-Hodgkin's lymphomas.
  • B-cell lymphoma include diffuse large B-cell lymphoma, follicular lymphoma, mucosa-associated lymphoid tissue lymphoma, small cell lymphocytic lymphoma, mantle cell lymphoma (MCL), Burkitt Lymphoma, mediastinal large B-cell lymphoma, Waldenstrom's macroglobulinemia, lymph node marginal zone B-cell lymphoma, splenic marginal zone lymphoma, intravascular large B-cell lymphoma, primary effusion lymphoma, lymphomatoid granuloma.
  • T cell lymphoma examples include extranodal T cell lymphoma, cutaneous T cell lymphoma, anaplastic large cell lymphoma, and angioimmunoblastic T cell lymphoma.
  • Hematological malignancies also include leukemias such as, but not limited to, secondary leukemia, chronic lymphocytic leukemia, acute myeloid leukemia, chronic myelogenous leukemia, and acute lymphoblastic leukemia.
  • Hematologic malignancies also include myelomas such as, but not limited to, multiple myeloma and smoldering multiple myeloma. The term hematological malignancies encompasses other blood and/or B or T cell related cancers.
  • the hybridoma cell line that can produce the antibody combined with 4-1BB was screened by hybridoma technology and ELISA method. Briefly, human recombinant protein 4-1BB (UniProtKB-Q07011) was mixed with complete Freund's adjuvant or incomplete Freund's adjuvant to form an emulsion, and injected subcutaneously in Balb/c mice. After 2-4 times of immunization, the binding titer of mouse serum to human recombinant protein 4-1BB was determined by ELISA method.
  • the spleen of the mouse can be obtained, and the spleen of the mouse can be fully ground to obtain a single cell suspension, which can be fused with myeloma cells to form hybridoma cells by PEG.
  • the culture supernatant of the hybridoma cells is detected by ELISA method, and the positive cells meeting the standard are selected to continue culturing.
  • the above-mentioned ELISA positive cell supernatant was obtained for the second time, and the FACs method was used to detect the binding of the antibody in the supernatant to the stably transfected CHO cell line highly expressing 4-1BB.
  • Table 2 shows the CDR sequences of the six antibodies screened based on the Kabat definition rules.
  • Example 2 Binding of the disclosed antibody to a CHO cell line stably transfected with human 4-1BB
  • the antibodies HEC500, HEC501, HEC502, HEC503, HEC504, and HEC505 screened in Example 1 were detected by flow cytometry, and they were highly expressed in human 4-1BB (UniProtKB-Q07011) stably transfected CHO cell lines binding ability. After the antibody was incubated with the cells, the FITC-labeled goat anti-mouse IgG Fc secondary antibody was used to bind, the isotype IgG antibody was used as a negative control, and the anti-4-1BB antibodies Urelumab (BMS Company) and Utomilumab (Pfizer Company) were used as positive control. The results are shown in Figure 1.
  • Example 3 ELISA binding of antibodies of the present disclosure to monkey-derived 4-1BB recombinant protein
  • ELISA was used to detect the binding ability of the antibody to the recombinant protein of cynomolgus monkey 4-1BB (XP_005544947.1).
  • the recombinant 4-1BB protein was coated on a microtiter plate and left overnight at 4°C. After 3 washes, spin dry, seal at 37°C for 1 hour, wash 3 times, spin dry for later use. Incubate each antibody with the above spare microtiter plate at 4°C for 2 hours. After washing for 3 times, spin dry, and then bind with HRP-labeled goat anti-mouse IgG (Abcam: ab97023) secondary antibody. An isotype IgG antibody was used as a negative control, and Urelumab and Utomilumab antibodies were used as control samples. The results are shown in Figure 2.
  • T cells were isolated from human-derived peripheral blood mononuclear cell (PBMC) cell populations. T cells were stimulated in vitro for 48-72 hours using CD3 and CD28 antibody-coupled magnetic beads (Invitrogen-11161D). Antibodies HEC500, HEC501, HEC502, HEC503, HEC504, and HEC505 were incubated with T cells, respectively, and then PE-labeled goat anti-mouse IgG Fc secondary antibody (Jackson) was used to bind, and an isotype IgG antibody was used as a negative control. Urelumab and Utomilumab antibodies were used as control samples. Then, using a flow cytometer, the ability of the antibodies HEC500, HEC501, HEC502, HEC503, HEC504 and HEC505 to bind to the stimulated T cells was detected. The results are shown in FIG. 3 .
  • the Anti-CD3 antibody was pre-coated on the microtiter plate, and then the isolated human T cells were added, and the antibody diluted in a concentration gradient was added for incubation. Three days later, the expression level of IL2 in the supernatant was detected. Isotype IgG antibody (Isotype IgG) was used as a negative control, and Urelumab and Utomilumab antibodies were used as control samples. The results are shown in FIG. 4 .
  • the antibody of the present disclosure can activate T cells derived from the body in a concentration-dependent manner and secrete IL2 cytokines at a lower dose.
  • the Anti-CD3 antibody was pre-coated on the microtiter plate, and then the isolated human T cells were added, and the antibody diluted in a concentration gradient was added for incubation. Three days later, the expression of IFN- ⁇ in the supernatant was detected.
  • An isotype IgG antibody was used as a negative control, and Urelumab and Utomilumab antibodies were used as control samples. The results are shown in FIG. 5 .
  • the antibody of the present disclosure can activate T cells derived from the body in a concentration-dependent manner and secrete IFN- ⁇ cytokine at a lower dose.
  • humanized antibodies HEC501 and HEC502 were prepared according to conventional techniques in the art.
  • variable region sequences of HEC501 and HEC502 and their humanized mutant sequences were obtained by whole gene synthesis.
  • the HCDR sequences and LCDR sequences of the humanized antibodies obtained based on the HEC501 antibody are shown in Table 3.
  • the HCDR sequences and LCDR sequences of the humanized antibodies obtained based on the HEC502 antibody are shown in Table 4.
  • the variable region sequences of HEC501 and HEC502 were humanized to obtain the heavy chain variable region (HV) and light chain variable region (LV) shown in Table 5 and Table 6.
  • the constant region sequence required for the antibody comes from human IgG4 (EU: S228P), in which, the constant region of the heavy chain of the HEC501 humanized antibody is SEQ ID NO: 145; the constant region of the light chain of the HEC501 humanized antibody is SEQ ID NO: 146
  • the complete sequence of the humanized antibody can be obtained by directly splicing the constant region sequence with the humanized heavy chain variable region and light chain variable region shown in Table 5.
  • the constant region sequence required for the antibody comes from human IgG1, wherein the constant region of the heavy chain of the HEC502 humanized antibody is SEQ ID NO: 158; the constant region of the light chain of the HEC502 humanized antibody is SEQ ID NO: 159; the constant region sequence is the same as
  • the complete sequence of the humanized antibody can be obtained by directly splicing the humanized heavy chain variable region and light chain variable region shown in Table 6.
  • the resulting construct was transiently transfected into HEK293 cells.
  • chimeric antibodies and humanized antibodies with a purity of more than 95% were obtained (wherein HEC51118 and HEC51225 are chimeric antibody chains).
  • the expression level of the humanized antibody of the present disclosure was detected by conventional methods.
  • Table 10 shows the detection results of the expression level of the HEC501 humanized antibody.
  • Table 11 shows the detection results of the expression level of the HEC502 humanized antibody.
  • Example 8 ELISA binding of humanized antibody of the present disclosure to human 4-1BB protein and CHO cell line with high expression of 4-1BB.
  • a flow cytometer was used to detect the binding ability of the humanized antibody obtained in Example 7 to a stably transfected CHO cell line with high expression of human 4-1BB. After the antibody was incubated with the cells, the FITC-labeled goat anti-human IgG Fc secondary antibody was used to bind, and the isotype IgG antibody (Isotype IgG) was used as a negative control. The results are shown in Table 12 and Figure 6.
  • the binding ability of the humanized antibody obtained in Example 7 to the human 4-1BB (UniProtKB-Q07011) recombinant protein was tested using ELISA.
  • the recombinant 4-1BB protein was coated on a microtiter plate and left overnight at 4°C. After 3 washes, spin dry, seal at 37°C for 1 hour, wash 3 times, spin dry for later use. Incubate the antibody with the above spare ELISA plate at 4°C for 2 hours, wash it three times and then spin dry. Subsequently, HRP-labeled goat anti-human IgG Fc secondary antibody was used for binding, and isotype IgG antibody (Isotype IgG) was used as a negative control. The results are shown in Table 13.
  • Example 9 Detecting the binding of the humanized antibody of the present disclosure to the CHO cell line with high expression of 41BB after heat treatment at 65°C for 5 minutes
  • Antibody samples at a concentration of 1 mg/ml were treated with different phosphate, citrate or acetate buffers at pH 5, 6, 7, 8 or 9 at 65°C for 5 minutes.
  • the binding ability of the antibody to the CHO cell line stably transfected with human 4-1BB was detected.
  • the activity retention rate (%) of the sample after heat treatment was calculated using the respective numbered samples which had not been heat-treated in pH 7.4 buffer solution as the denominator. The results are shown in Table 14.
  • Embodiment 10 Biofilm light interference technique (Bio-Layer Interferometry, BLI) measures affinity
  • Example 11 Anti-tumor activity evaluation of the tested antibody in the tumor-bearing humanized mouse model of MC38 high-expression GPC3 stably transfected cell line
  • Example 12 Anti-tumor activity evaluation of the tested antibody in the tumor-bearing humanized mouse model of MC38 high expression GPC3 stably transfected cell line

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)

Abstract

L'invention concerne un anticorps agoniste anti-4-1BB et son utilisation, un anticorps agoniste anti-4-1BB humanisé ou une partie de liaison à l'antigène de celui-ci, et l'utilisation des anticorps ou des parties de liaison à l'antigène de ceux-ci dans le traitement de cancers.
PCT/CN2022/116428 2021-09-09 2022-09-01 Anticorps agoniste anti-4-1bb et son utilisation Ceased WO2023036041A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN202111053393 2021-09-09
CN202111053393.9 2021-09-09

Publications (1)

Publication Number Publication Date
WO2023036041A1 true WO2023036041A1 (fr) 2023-03-16

Family

ID=85507224

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2022/116428 Ceased WO2023036041A1 (fr) 2021-09-09 2022-09-01 Anticorps agoniste anti-4-1bb et son utilisation

Country Status (2)

Country Link
CN (2) CN116253799B (fr)
WO (1) WO2023036041A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117736330B (zh) * 2024-01-24 2024-05-17 上海沙砾生物科技有限公司 肿瘤坏死因子超家族受体9的特异性抗原结合蛋白及其应用

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101528779A (zh) * 2006-10-16 2009-09-09 斯克利普斯研究院 炎症性疾病中的4-1bb配体
CN108473587A (zh) * 2016-01-25 2018-08-31 辉瑞公司 用于治疗癌症的ox40激动剂和4-1bb激动剂单克隆抗体的组合
WO2018213747A1 (fr) * 2017-05-19 2018-11-22 Merrimack Pharmaceuticals, Inc. Molécules bispécifiques agonistes de 4-1bb et de cd40
CN109651507A (zh) * 2017-10-12 2019-04-19 瑞阳(苏州)生物科技有限公司 一种激动型4-1bb单克隆抗体
WO2020007817A1 (fr) * 2018-07-04 2020-01-09 F. Hoffmann-La Roche Ag Nouvelles molécules de liaison à l'antigène 4-1bb bispécifiques
US20210107982A1 (en) * 2019-10-11 2021-04-15 Nanjing Leads Biolabs Co., Ltd. Antibodies binding 4-1bb and uses thereof
WO2021098597A1 (fr) * 2019-11-19 2021-05-27 非同（成都）生物科技有限公司 Anticorps monoclonal humanisé 4-1bb et composition pharmaceutique associée

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030096976A1 (en) * 1998-11-17 2003-05-22 Hong Hyo Jeong Humanized antibodies LB-00503 and LB-00506 specific for human 4-1BB and pharmaceutical compositions comprising said humanized antibodies
JP2021510533A (ja) * 2018-01-22 2021-04-30 江蘇恒瑞医薬股▲ふん▼有限公司 抗４−１ｂｂ抗体、その抗原結合フラグメント、およびその医学的使用
CN110357961B (zh) * 2018-04-10 2022-08-23 无锡智康弘义生物科技有限公司 抗人4-1bb单克隆抗体及其制备方法和用途
WO2021013142A1 (fr) * 2019-07-22 2021-01-28 江苏恒瑞医药股份有限公司 Anticorps anti-4-1bb, fragment de liaison à l'antigène de celui-ci et anticorps bispécifique

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101528779A (zh) * 2006-10-16 2009-09-09 斯克利普斯研究院 炎症性疾病中的4-1bb配体
CN108473587A (zh) * 2016-01-25 2018-08-31 辉瑞公司 用于治疗癌症的ox40激动剂和4-1bb激动剂单克隆抗体的组合
WO2018213747A1 (fr) * 2017-05-19 2018-11-22 Merrimack Pharmaceuticals, Inc. Molécules bispécifiques agonistes de 4-1bb et de cd40
CN109651507A (zh) * 2017-10-12 2019-04-19 瑞阳(苏州)生物科技有限公司 一种激动型4-1bb单克隆抗体
WO2020007817A1 (fr) * 2018-07-04 2020-01-09 F. Hoffmann-La Roche Ag Nouvelles molécules de liaison à l'antigène 4-1bb bispécifiques
US20210107982A1 (en) * 2019-10-11 2021-04-15 Nanjing Leads Biolabs Co., Ltd. Antibodies binding 4-1bb and uses thereof
WO2021098597A1 (fr) * 2019-11-19 2021-05-27 非同（成都）生物科技有限公司 Anticorps monoclonal humanisé 4-1bb et composition pharmaceutique associée

Also Published As

Publication number Publication date
CN116253799B (zh) 2024-04-26
CN118684772A (zh) 2024-09-24
CN116253799A (zh) 2023-06-13

Similar Documents

Publication Publication Date Title
US10233258B2 (en) Bispecific binding proteins that bind CD40 and mesothelin
JP2021522801A (ja) ヒトネクチン４に特異的な抗体
US11655295B2 (en) Anti-LAG-3 antibody and use thereof
US20240067740A1 (en) Antibodies to tnfr2 and uses thereof
JP2023520587A (ja) 癌及び感染症の治療のためのＮＫｐ４６に対する抗体及びそのコンストラクト
TW202313699A (zh) 新型抗ｓｉｒｐａ抗體
KR20230015328A (ko) 항-ox40 항체 및 이의 용도
CN116199778B (zh) 抗4-1bb抗体及其用途
EP4389770A1 (fr) Anticorps bispécifique et son utilisation
CN116253799B (zh) 抗4-1bb的激动型抗体及其应用
KR20240026185A (ko) 항-cd40 항체, 항원 결합 단편 및 이의 의학적 용도
CA3182362A1 (fr) Anticorps anti-cd25, fragments de liaison a l'antigene associes et utilisations medicales associees
CN116419970B (zh) 低毒性抗ox40抗体、其药物组合物及应用
CN114641500B (zh) 使用抗ox40抗体与抗tim3抗体的组合治疗癌症的方法
CN115960242B (zh) 抗癌结合分子及其应用
CN114729051A (zh) 使用抗ox40抗体与放射组合治疗癌症的方法
EP3904383A1 (fr) Anticorps monoclonal anti-ox40 et utilisation associée
CN112512572A (zh) 抗cd40抗体及其用途
JP7688150B2 (ja) 抗ＯＸ４０Ｌ抗体、抗ＯＸ４０Ｌ及び抗ＴＮＦαの二重特異性抗体、並びにこれらの用途
CN118852427A (zh) 靶向cd70的单克隆抗体及其用途
CN119661708A (zh) 靶向cd27的单克隆抗体及其用途
CN118922444A (zh) 抗ccr8抗体
HK40034214B (en) Anti-lag-3 antibody and use thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 22866505

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 22866505

Country of ref document: EP

Kind code of ref document: A1